100s of titles, one news app for just $10 a month.
Dive Deeper:
Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00…
Needham Maintains Buy Rating for GLOBALFOUNDRIES: Here's What You Need To Know
Needham has decided to maintain its Buy rating of GLOBALFOUNDRIES (NASDAQ:GFS) and lower its price target from $87.00 to $70.00.…
Deutsche Bank Maintains Buy Rating for Nomad Foods: Here's What You Need To Know
Deutsche Bank has decided to maintain its Buy rating of Nomad Foods (NYSE:NOMD) and raise its price target from $25.00…
Raymond James Maintains Outperform Rating for MeridianLink: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of MeridianLink (NYSE:MLNK) and lower its price target from $27.00 to…
One subscription that gives you access to news from hundreds of sites
Oppenheimer Maintains Outperform Rating for IAC/InterActive: Here's What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of IAC/InterActive (NASDAQ:IAC) and lower its price target from $155.00 to $135.00.…
Keybanc Maintains Overweight Rating for Walt Disney: Here's What You Need To Know
Keybanc has decided to maintain its Overweight rating of Walt Disney (NYSE:DIS) and lower its price target from $216.00 to…
Get all your news in one place
Latest Business news:
Bitcoin Recovers After Longest Run of Weekly Losses Since 2011
Bitcoin recovered to trade just above the $30,000 level where it’s been mostly hovering since the collapse of the TerraUSD…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
How to Make Money (or Even Get Rich) During a Stock Market Crash
A crash creates buying opportunities if you can develop the right mindset.
HSBC suspends head of responsible investing who called climate warnings ‘shrill’
Bank investigating Stuart Kirk’s conference speech deriding flooding risks and climate warnings from UN and Bank of England
Star board 'misplaced' trust in management
An inquiry into Star Entertainment Group's Sydney casino has been told there were not enough "fresh eyes" to curb mismanagement…
After $5 Trillion Rout, Emerging Markets Seek Turnaround Signal
The wreckage of a $5 trillion rout in emerging markets is starting to look like a buying opportunity to some…
From analysis to good news, read the world’s best news in one place
New Zealand PM Ardern to visit U.S. to boost exports, lure tourists
New Zealand Prime Minister Jacinda Ardern will visit the United States this week in a bid to boost exports and…
Rod Sims says Facebook should be forced to negotiate with SBS under news media bargaining code
Despite dozens of deals to pay Australian news publishers for content, social media company has left out SBS and the…

Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here's What You Need To Know

By Benzinga Insights

Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00 to $12.00.

Shares of Cytek Biosciences are trading up 10.93% over the last 24 hours, at $8.22 per share.

A move to $12.00 would account for a 45.99% increase from the current share price.

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00…
Needham Maintains Buy Rating for GLOBALFOUNDRIES: Here's What You Need To Know
Needham has decided to maintain its Buy rating of GLOBALFOUNDRIES (NASDAQ:GFS) and lower its price target from $87.00 to $70.00.…
Deutsche Bank Maintains Buy Rating for Nomad Foods: Here's What You Need To Know
Deutsche Bank has decided to maintain its Buy rating of Nomad Foods (NYSE:NOMD) and raise its price target from $25.00…
Raymond James Maintains Outperform Rating for MeridianLink: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of MeridianLink (NYSE:MLNK) and lower its price target from $27.00 to…
One subscription that gives you access to news from hundreds of sites
Oppenheimer Maintains Outperform Rating for IAC/InterActive: Here's What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of IAC/InterActive (NASDAQ:IAC) and lower its price target from $155.00 to $135.00.…
Keybanc Maintains Overweight Rating for Walt Disney: Here's What You Need To Know
Keybanc has decided to maintain its Overweight rating of Walt Disney (NYSE:DIS) and lower its price target from $216.00 to…
Get all your news in one place